Literature DB >> 20032221

Rituximab: a potential therapeutic advance in scleroderma: what is the evidence?

Robert W Simms, Robert Lafyatis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20032221     DOI: 10.1093/rheumatology/kep421

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  2 in total

1.  Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo.

Authors:  Dimitrios Daoussis; Andrew P Andonopoulos
Journal:  Rheumatol Int       Date:  2010-04-08       Impact factor: 2.631

2.  Egr-ly awaiting a "personalized medicine" approach to treat scleroderma.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2012-02-15       Impact factor: 5.782

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.